Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — Investor Presentation (September 2026)
17 slides from Scienture's investor presentation, Sep 14, 2026
Slide 1: Scienture Holdings
#3 Scienture Holdings We invest in creating better health outcomes NASDAQ: SCNX
Slide 2: Safe Harbor Statement and Non-GAAP Measures
Safe Harbor Statement and Non-GAAP Measures ‘The information set forth herein contains forward-looking statements within the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that d
Slide 3: Scienture Holdings, Inc | About Us
Scienture Holdings, Inc | About Us Scienture Holdings is a fully integrated pharmaceutical product group committed to providing greater value to patients, physicians, and caregivers through the development, commercialization, and distribution of innovative specialty products designed to meet unmet c
Slide 4: Leadership
Leadership Executive Management Shankar Hariharan, Ph.D. Executive Chairman & Co-CEO, Director Over 35 years of experience in Pharmaceutical Industry. Involved with development and commercialization of Celexa® (°$2B), Lexapro® ($4B), Namenda® (>$2B), Megace ES® (>$100M). He has founded and has held
Slide 5: Our Mission
Our Mission Our mission is to bring patients selectively designed drug product innovations through accelerated nuanced commercialization by channeling the power of technology platforms Beginnings Our founders identified critical gaps in care—challenging treatment paradigms, safety and efficacy limit
Slide 6: Prioritizing Patients.
Prioritizing Patients. 33} Scienture Improving Outcomes. (a wholly owned subsidiary of Scienture Holdings, Inc.)
Slide 7: Delivering Better™ | Improving today's medicines for a better tomorrow
Delivering Better™ | Improving today’s medicines for a better tomorrow We fuse our core capabilities to these cornerstones, delivering scientific and commercial solutions, addressing gaps in therapy treatment, and leading to better health outcomes. o-6 za » Data-Driven cl Insights Champion 7 7 Leer
Slide 8: Product Portfolio
Product Portfolio Anticipated Early Animal Human Studies NDA/ BLA Anticipated Product I Indication Development Studies Phase 1 Phase 2 Phase 3 Timeline Launch Arbli™ | CVS/Hypertension © NotKaqaked Mar 2025 Oct 2025 Oral suspension for geriatric and pediatric use (Approved) (Launched) monies TS tec
Slide 9: Intellectual Property | USPTO Granted Patents and Pending Applications
Intellectual Property | USPTO Granted Patents and Pending Applications + Arbli™ (SCN-102) + Patent #: 11,890,273, Issue Date: February 6, 2024, titled “LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE”, Expiration Date: October 7, 2041 + Patent #: 12,156,869; Issue Date: December 3, 2024, titled “LOS
Slide 10: Arbli™ (losartan potassium) Oral Suspension
Arbli™ (losartan potassium) Oral Suspension 10 mg / mL 165 mL bottle The first and only FDA approved liquid losartan formulation available in the US Market First and only liquid ARB | FDA Approved March 13, 2025 Successfully commercially launched Arbli™ in October 2025 Arbli” (losartan potassium) Or
Slide 11: REZENOPY™ (Naloxone HCl) Nasal Spray, 10mg
REZENOPY™ (Naloxone HCl) Nasal Spray, 10mg The Highest FDA-approved Dose per nasal spray for Naloxone in the US market ‘The Maximum-Dose Naloxone Solution for your formulary | FDA Approved April 24, 2024; Launched in August 2026 i (- {naloxone HC!) Visit REZENOPY.com for ordering information and res
Slide 12: Commercial Operations | Strategy & Execution
Commercial Operations | Strategy & Execution A sound strategy in place for a robust coordinated commercial execution Promotional + Branding + Patient + HCP Narratives ~ + Brand Institute Logo and Naming Development + Value Proposition Development = Data-Driven Insights + IQVANSPINPA Insights/DDD dat
Slide 13: SCN-104 | Fixed Dose Injection Pen
SCN-104 | Fixed Dose Injection Pen Product Description Therapeutic Area US Market Easy-to-use, multi-dose pen ‘CNS (Migraine) Total US Market for Migraine in based delivery system for self Indicated for acute treatment of 2025 was $1.2Bn growing to injection and increased migraine headaches with or
Slide 14: SCN-106 | Biosimilar Product
SCN-106 | Biosimilar Product Product Description Therapeutic Area US Market Large Molecule Biosimilar Cardiovascular (hospital based) Total Addressable Market Size for CV use (IQVIA Feb 2026)—$636MM Value Proposition sea 1) Once an equivalent product is Potential to be the First to Market Biosimilar
Slide 15: SCN-107 | Extended-Release Injection
SCN-107 | Extended-Release Injection Product Description Microsphere based long-acting injection with immediate release ‘component Value Proposition On Potential reduction to opioid usage following surgeries Therapeutic Area US Market CNS (Post surgical pain) Total Addressable Market Size Indicated
Slide 16: Strong Financial Momentum
Strong Financial Momentum Rapid revenue growth, high gross margins and improving operating performance Quarterly Revenue $400,000 ~510% Sequential Revenue Growth $300,000 Q1 2026 vs Q2 2026 $200,000 ~989 $100,000 98% Gross Margin $0,0 ™Q12026 mQ22026 i) ~41% h ~58% = $11.2M Lower Operating Expenses
Slide 17: Thank you!
Thank you! SCIENTURE HOLDINGS, INC. 20 Austin Blvd Commack, NY 11725 Phone: (866) 468-6535 Email: IR@Scienture.com www.scienture.com $$ Scienture Holdings Nasdagq:SCNX
Scienture Holdings — Investor Presentation (September 2026) on 6ix